Physician profile
William D Johnson
NPI 1255371944
$2,806.30
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,143 · 2020: $261 · 2021: $87.22 · 2022: $55.03 · 2023: $173 · 2024: $87.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238 · Education: $22.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.81 |
| Education | $22.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.17 | 2021-2024 | |
| Pfizer INC. | $338.08 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $258.81 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.02 | 2019-2020 | |
| Lilly USA, LLC | $180.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $174.37 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.07 | 2019 | |
| Amgen INC. | $147.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $146.64 | 2019 | |
| Glaxosmithkline, LLC. | $144.02 | 2019-2020 | |
| Novo Nordisk INC | $128.20 | 2019-2020 | |
| Daiichi Sankyo INC. | $95.25 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $75.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $65.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.22 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.00 | 2019 | |
| Amarin Pharma, INC. | $39.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.18 | 2019 | |
| Indivior INC. | $32.92 | 2019 | |
| Lundbeck LLC | $22.65 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $15.50 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.29 | 2020 | |
| Boston Scientific Corporation | $14.58 | 2019 | |
| Merck Sharp & Dohme LLC | $13.30 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Gilead Sciences, INC. | $12.71 | 2020 | |
| Ironwood Pharmaceuticals, INC | $12.24 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.69 | 2020 | |
| Shire North American Group INC | $11.22 | 2019 | |
| Mylan Specialty L.P. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.